Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Cognition Therapeutics Q2 EPS $(0.11), Inline

Author: Benzinga Newsdesk | August 07, 2025 03:10pm
Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.11) per share which met the analyst consensus estimate. This is a 38.89 percent increase over losses of $(0.18) per share from the same period last year.

Posted In: CGTX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist